

used either individually or conjugated to drugs, labels, radioisotopes, or cytotoxins to target delivery of the conjugated to prostate cells. The antibodies are thus useful in a variety of diagnostic and therapeutic applications involving prostate cancer. A hybridoma cell line secreting monoclonal antibody PR1 is also provided, as well as methods for screening for the presence of metastatic prostate cancer. [portfolio: Cancer—Therapeutics]

Antibodies To Human LINE-1 p40 Protein

Fanning, T.G. (NCI)
Serial No. 07/750,044
Patent Issued 18 Jan 94
U.S. Patent No. 5,280,108

Antibodies to the human LINE-1 retrotransposon offer a powerful new tool for studying tumors. In most cell lines and tissues, human LINE-1 sequences (LIHs) are not expressed; however, LIH-specific RNA and proteins have been detected in cell lines and tissues derived from human germ cell tumors (teratocarcinomas) and breast tumors. These LIH antibodies, which are specific for the p40 protein portion of the retrotransposon, can be used for determining LIH expression in tumor cells and determining the role this retrotransposon plays in these cells. [portfolio: Cancer—Research Reagents]

Cartilage-Derived Morphogenetic Proteins

Luyten, F.P., Moos, M., Chang, S. (NIDR)
PCT Application PCT/US94/12814 filed 7 Nov 94
DHHS Reference No.: E-138-94/0

The present invention provides a cartilage-derived extract which initiates and promotes ectopic cartilage and bone development *in vivo* and recombinant cartilage-derived morphogenetic proteins which promote development of musculoskeletal tissues *in vivo*. These products will be useful in the therapeutic induction, repair, and maintenance of skeletal tissues. These compounds show promise for the healing of joint surface lesions and repair or reconstruction of cartilaginous tissues. They are also useful as growth factors for cells of the chondrocyte lineage which, expanded *ex vivo*, can be implanted into an individual where cartilage growth is desired. In addition, cloned polynucleotides encoding these proteins will be effective diagnostic reagents for detecting genetic abnormalities associated with poor skeletal development. [portfolio: Cancer—Therapeutics, biological response modifiers, growth factors]

Dated: November 20, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-29092 Filed 11-28-95; 8:45 am]
BILLING CODE 4140-01-P

National Cancer Institutes; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Cancer Institute Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: Subcommittee D—Clinical Research Studies.

Date: December 11–12, 1995.

Time: 8 a.m.

Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: John Abrell, Ph.D., 6130 Executive Blvd., Room 635B, Bethesda, MD 20892, telephone: 301-496-9767.

Committee Name: Subcommittee H—Clinical Trials.

Date: December 12–13, 1995.

Time: 8 a.m.

Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: John L. Meyer, Ph.D., 6130 Executive Blvd., Room 611C, Bethesda, MD 20892, telephone: 301-496-7721.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(CATALOG OF FEDERAL DOMESTIC ASSISTANCE PROGRAM NUMBERS: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: November 21, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-29090 Filed 11-28-95; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute

Frederick Cancer Research & Development Center Advisory Committee.

Agenda/Purpose: Discussion of previous site visit report and response for the AIDS Vaccine program and AIDS projects both under contract with Science Applications International Corporation, site visit review of the Macromolecular Structure Laboratory with Advanced Bioscience Laboratories, Inc.

Committee Name: Frederick Cancer Research & Development Center Advisory Committee.

Date: December 11–13, 1995.

Time: Open Session, Dec. 11–8:30 a.m.–11:00 a.m.; closed session, Dec. 11–11 a.m.–Dec. 13.

Place: Frederick Cancer Research and Development Center, Building 549, Executive Board Room, Frederick, MD 21702.

Contact Person: Cedric W. Long, Ph.D., Frederick Cancer Research and Development Center, P.O. Box B, Frederick, MD 21702, telephone: 301-496-1108.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The reports and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(CATALOG OF FEDERAL DOMESTIC ASSISTANCE PROGRAM NUMBERS: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: November 21, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-29091 Filed 11-28-95; 8:45 am]

BILLING CODE 4140-01-M

Substance Abuse and Mental Health Services Administration

Proposed Data Collection Available for Public Comment

In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 to provide the opportunity for public comment on proposed data collection projects, the Substance Abuse and Mental Health Services Administration publishes periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the SAMHSA Reports Clearance Officer on (301) 443-0525.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance